Diabetes under control: Understanding oral antidiabetic agents.
Longo
Rebecca
R
rlibbyrick@mac.com
D000284:Administration, Oral; D001645:Biguanides / Q000627:therapeutic use; D002219:Carbamates / Q000627:therapeutic use; D003510:Cyclohexanes / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use*; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
D001645:Biguanides; D002219:Carbamates; D003510:Cyclohexanes; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004338:Drug Combinations; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D010880:Piperidines; D013453:Sulfonylurea Compounds; D000077715:Nateglinide; D010649:Phenylalanine; C072379:repaglinide